期刊文献+

直肠癌新辅助放化疗后病理完全缓解预测因素分析 被引量:20

Predictive factors associated with pathologic complete response after neoadjuvant chemoradiotherapy in rectal cancer
原文传递
导出
摘要 目的探讨影响直肠癌新辅助放化疗后病理完全缓解的相关预测因素。方法回顾性分析2007年1月至2013年5月间福建医科大学附属协和医院结直肠外科同一组医师收治的163例直肠癌新辅助放化疗及手术的临床资料。采用单因素分析及Logistic多因素分析法研究病理完全缓解(pCR)的相关预测因素。结果全组患者新辅助放化疗后有29例(17.8%,29/163)达pCR。单因素分析结果显示,肿瘤占据肠腔环周比例小于或等于1/2周(P=0.018)、病理类型为非黏液腺癌(P=0.036)、分化程度为高分化或中分化(P=0.021)及放化疗前CEA小于或等于2.5μg/L(P=-0.007)与直肠癌新辅助放化疗后高pCR率有关。多因素回归分析结果显示,肿瘤占据肠腔环周比例小于或等于1/2周(OR=2.901,P=0.020)和放化疗前CEA小于或等于2.5μg/L(OR=2.775,P-0.022)是影响直肠癌新辅助放化疗后pCR的独立因素。结论肿瘤占据肠腔环周比例和放化疗前CEA检测水平有助于预测直肠癌新辅助放化疗后的pCR率。 Objective To explore predictive factors associated with pathologic complete response (pCR) after neoadjuvant chemoradiotherapy for rectal cancer. Methods Clinicopathological data of 163 patients with locally advanced rectal cancer who were treated with neoadjuvant chemoradiotherapy followed by radical surgical resection from January 2007 to May 2013 were analyzed retrospectively. Univariate analysis and multivariate logistic regression analysis were performed to analyze associated factors of pCR, including age, gender, body mass index (BMI), diabetes, anemia, tumor diameter, distance of the tumor from the anal verge, circumferential extent of the tumor, tumor pathological types, tumor differentiation, pre-chemoradiotherapy T stage, pre-chemoradiotherapy N stage, preehemoradiotherapy CEA level, pre-chemoradiotherapy CA199 level, per-operation CEA level, preoperation CA199 level, radiation dose, chemotherapy modality, time interval from completion of chemoradiotherapy to surgery, etc. Results Twenty-nine patients (17.8%) achieved pCR after neoadjuvant chemoradiotherapy for rectal cancer. Univariate analysis showed circumferential extent of tumor ( ≥1/2 cycle) (P=0.018), tumor pathological types (adenocarcinoma) (P=0.036), tumor differentiation (moderate or high)(P=0.021) and pre-chemoradiotherapy CEA level (≤2.5 μg/L)(P=0.007) were significantly correlated with pCR after neoadjuvant chemoradiotherapy for rectal cancer. Logistic regression revealed that circumferential extent of tumor (≥ 1/2 cycle)(OR=2.901, P=0.020) and prechemoradiotherapy CEA level (≤2.5 μg/L)(OR=2.775, P=0.022) were independent predictive factors of pCR after neoadjuvant chemoradiotherapy for rectal cancer. Conclusion Patients with circumferential extent of tumor ≤1/2 and pre-chemoradiotherapy CEA level ≤2.5 μg/L are more likely to achieve pCR after neoadjuvant chemoradiotherapy for rectal cancer, and these two indices can be used to predict pCR after neoadjuvant chemoradiotherapy for rectal cancer.
出处 《中华胃肠外科杂志》 CAS CSCD 2014年第6期556-560,共5页 Chinese Journal of Gastrointestinal Surgery
基金 卫生部国家临床重点专科建设资助项目(卫办医政函[2012]649号)
关键词 直肠肿瘤 新辅助治疗 病理完全缓解 多因素分析 Rectal neoplasms Neoadujvant chemoradiotherapy Pathologic complete response Multivariate analysis
  • 相关文献

参考文献15

  • 1董功航,兰平,汪建平.中低位直肠癌术前放化疗现状[J].中国实用外科杂志,2008,28(2):149-150. 被引量:21
  • 2van Gijn W, Marijnen CA, Nagtegaal 1D, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the muhicentre, randomised controlled TME trial [J]. Lancet Oncol, 2011,12: 575-582.
  • 3Saner R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years [J]. J Clin Oncol, 2012,30: 1926-1923.
  • 4De Paolie A, Innoeente R, Buonadonna A, et al. Neoadjuvant therapy of rectal cancer new treatment perspectives[J]. Tumori, 2004,90 : 373-378.
  • 5Guillem JG, Chessin DB, Cohen AM, et al. Long-term oncologic outcome following preoperative combined modality therapy and total mesoreetal excision of locally advanced rectal cancer[J]. Ann Surg, 2005,24l : 829-838.
  • 6Biondo S, Navarro M, Marti-Rague J, et al. Response to neoadjuvant therapy for rectal cancer: influence on long-term results [ J]. Colorectal Dis, 2005,7 : 472-479.
  • 7Wheeler JM, Warren BF, Mortensen NJ, et al. Quantification of histologic regression of rectal cancer after irradiation: a proposal for a modified staging system [J]. Dis Colon Rectum, 2002,45 : 1051 - 1056.
  • 8Capirei C, Valentini V, Cionini L, et al. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients [J ]. lnt J Radiat Oncol Biol Phys, 2008,72 : 99-107.
  • 9Das P, Skibber JM, Rodriguez-Bigas MA, et al. Predictors of.tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer [J]. Cancer, 2007,109 : 1750-1755.
  • 10Yan H, Wang R, Zhu K, et al. Predictors of sensitivity to preoperative chemoradiotherapy of rectal adenocarcinoma [J]. Tumori, 2011,97 : 717-723.

二级参考文献20

  • 1Wolpin BM, Meyerhardt JA, Mamon HI, et al. Adjuvant treatment of colorectal cancer. CA Cancer J Clin, 2007,57: 168-185.
  • 2Garcia-Aguilar J, Hernandez de Anda E, Sirivongs P, et al. A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision. Dis Colon Rectum, 2003,46: 298-304.
  • 3Mehta VK, Cho C, Ford JM, et al. Phase Ⅱ trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. Int J Radiat Oncol Biol Phys, 2003,55 : 132-137.
  • 4Gerard JP, Chapet O, Nemoz C, et al. Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase Ⅱ trial. J Clin Oncol, 2003,21:1119- 1124.
  • 5Kudrimoti M, Lee EY, Kang Y, et al. Genetic markers predictive of response to induction chemoradiotherapy for locally advanced rectal cancers. J Ky Med Assoc, 2007, 105: 18-22.
  • 6Bertolini F, Bengala C, Losi L, et al. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Radiat Oncol Biol Phys, 2007,68:1455-1461.
  • 7Klautke G, Feyerherd P, Ludwig K, et al. Ntensified concurrent chemoradio-therapy with 5-fluorouracil and ifinotecan as neoadjuvant treatment in pat/ents with locally advanced rectal cancer [ J]. Br J Cancer,2005,92 (7) : 1215 - 1220.
  • 8Chau I, Brown G, Cunningham D,et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer [ J ]. J Clin Oncol,2006,24 (4) :668 - 674.
  • 9Hotheinz RD, Hofisberger K, Woemle C, et al. Phase I trial of cetuximab in combination with capecitabine, weekly ifinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer[J]. Int J Radiat Oncol Biol Phys,2006,66 (5) :1384 -1390.
  • 10Crane CH, Skibber JM, Bimbaum JH, et al. The addition of continuous infusion 5-FU to preoperative radiationtherapy increased tumor response, leading to increased sphincter preservation in locally- advanced rectal cancer[J]. Int J Radiat Oncol Biol Phys, 2003,57( 1 ) :84 - 89.

共引文献26

同被引文献144

  • 1姚云峰.肿瘤分期与疗效评价[J].中国医学前沿杂志(电子版),2010,2(4):70-75. 被引量:6
  • 2袁野,肖小炜.进展期结直肠癌的治疗现状[J].医学信息(西安上半月),2005,18(12):1762-1764. 被引量:3
  • 3孙凯,黄晓卉,甄茂川,汪谦.应用液相芯片分析肝细胞癌及癌旁组织小分子RNA表达谱差异[J].中华实验外科杂志,2006,23(8):945-947. 被引量:25
  • 4尹立杰,张力,丁田贵,彭兆祥,于环,高玉伟.甘氨双唑钠对乏氧胰腺癌细胞放射增敏研究[J].中华放射医学与防护杂志,2006,26(5):467-470. 被引量:5
  • 5刘孟忠,何立儒,卢泰祥,陈媛媛,胡永红,崔念基,徐国镇,高黎,肖光莉,张姗文,蔡勇,李东明,陈龙华,王凤英,孙菁,朱莉,申戈,高红军,鲍云华.甘氨双唑钠对鼻咽癌放疗增敏作用的长期疗效[J].中华肿瘤杂志,2006,28(12):932-937. 被引量:28
  • 6中华医学会外科学分会胃肠外科学组,中华医学会外科学分会结直肠肛门外科学组,中国抗癌协会大肠癌专业委员会.结直肠癌肝转移诊断和综合治疗指南(V2010).中华胃肠外科杂志,2010,13:457-470.
  • 7Trotti A,Coleves AD,Setser A,et al.CTCAE v 3.0:development of a comprehensive grading system for the adverse effects of cancer treatment[J].Semin Raidat Oncol,2003,13(3):176-181.
  • 8Daiko H,Hayashi R,Saikawa M,et al.Surgical management of carcinoma of the cervical esophagus[J].J Surgical Oncol,2007,96:166-172.
  • 9Budach V,Stuschke M,Budach W,et al.Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer:final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial[J].J Clinical Oncology,2005,23(6):1125-1135.
  • 10Jeffrey ST,Kathryn M,Nirmal G,et al.Chemoradiotherapy for locally advanced head and neck cancer:10-year follow-up of the UK Head and Neck(UKHAN1)tri-al[J].Lancet Oncol,2010,11(1):66-74.

引证文献20

二级引证文献102

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部